The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Updated results from the RESTORE trial: elritercept in patients with MF receiving ruxolitinib
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares updated results from the Phase II RESTORE trial (NCT05037760) investigating the use of elritercept in patients with myelofibrosis (MF) receiving ruxolitinib. The results demonstrated the potential benefits of elritercept beyond anemia, including improvements in spleen volume, MF symptoms, and thrombocytopenia. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The RESTORE trial is an important study because it’s the first study we’ve done with the TGF-beta superfamily ligand trap, similar to luspatercept and sotatercept but different. So this study was the first study where we’ve used this agent, previously known as CUR-050, now known as elritercept. It may be familiar to listeners because it also has been used in MDS. So in the study, we used monotherapy and combination...
The RESTORE trial is an important study because it’s the first study we’ve done with the TGF-beta superfamily ligand trap, similar to luspatercept and sotatercept but different. So this study was the first study where we’ve used this agent, previously known as CUR-050, now known as elritercept. It may be familiar to listeners because it also has been used in MDS. So in the study, we used monotherapy and combination. And the data that’s presented at ASH 2015 is super, super exciting because not only does it solidify what we understand about the benefits of this drug, which we might expect to be anemia, but it actually extends beyond that. It includes anemia, spleen, symptoms, improvements in platelets. But what we saw at this meeting was some changes in the JAK2 V617F for some patients. So super exciting and a prelude to probably a phase three trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
